Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1539-1553

  Lu, Liangjian ^a   Yan, Haixi ^a   Shyam Sundar, Vijay ^a   Janowitz, Tobias ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer prevention; Cancer vaccination; Clinical trials; Immunotherapy; Translational trial endpoints

Indexed keywords

ALGENPANTUCEL L; BELAGENPUMATUCEL L; CANCER VACCINE; FALIMAREV; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HUMAN PAPILLOMAVIRUS 16 18 L1 VIRUSLIKE AS04 VACCINE; HUMAN PAPILLOMAVIRUS 16 18 L1 VIRUSLIKE PARTICLE VACCINE; HUMAN PAPILLOMAVIRUS V503 VACCINE; IMA 901; MITUMPROTIMUT T; NELIPEPIMUT S; RACOTUMOMAB; SEVIPROTIMUT L; TECEMOTIDE; TERTOMOTIDE; UNCLASSIFIED DRUG; VACCINIA VACCINE; WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER REGISTRY; CANCER RESEARCH; CROSS-SECTIONAL STUDY; DRUG FORMULATION; EXPERIMENTAL DESIGN; FACTUAL DATABASE; HUMAN; LONGITUDINAL STUDY; NEOPLASM; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY CONTROL; TREATMENT DURATION; TREATMENT INDICATION; US CLINICAL TRIAL DATABASE; VALIDATION PROCESS; BIOASSAY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PROCEDURES; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; ENDPOINT DETERMINATION; HUMANS; LONGITUDINAL STUDIES; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84908070945     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S65963     Document Type: Article

References (41)

1. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1-14.
2. Bilusic M, Gulley JL. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother. 2012;61(1):109-117.
3. Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther. 2012;19(6):e172-e181.
4. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011;239(1):27-44.
5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-2454.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
7. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212-20217.
8. Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol. 2013;40(4):482-491.
9. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol. 2012;23 Suppl 8(Suppl 8):viii47-viii52.
10. Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett. 2012;325(2):155-164.
11. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;104(8):599-613.
12. Balwit JM, Hwu P, Urba WJ, Marincola FM. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med. 2011;9:18.
13. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. Epub October 21, 2013.
14. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11(1):24-37.
15. Riley JL. Combination checkpoint blockade - taking melanoma immunotherapy to the next level. N Engl J Med. 2013:369(2):187-189.
16. Koos D, Josephs SF, Alexandrescu DT, et al. Tumor vaccines in 2010: need for integration. Cell Immunol. 2010;263(2):138-147.
17. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132-5136.
18. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
19. Marzbani E, Inatsuka C, Lu H, Disis ML. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila). 2013;6(8):764-773.
20. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009;19(5):275-282.
21. Liu MA. Cancer vaccines. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2823-2826.
22. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303-1310.
23. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev. 2008;222:316-327.
24. Sobol RE. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther. 2006;13(8):725-731.
25. Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1): 18-26.
26. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3(8):630-641.
27. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-1397.
28. Begg CB. Justifying the choice of endpoints for clinical trials. J Natl Cancer Inst. 2013;105(21):1594-1595.
29. von Elm E, Altman DG, Egger M, et al; Strobe Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457.
30. Li LM, Menon DK, Janowitz T. Cross-sectional analysis of data from the US clinical trials database reveals poor translational clinical trial effort for traumatic brain injury, compared with stroke. PLoS One. 2014;9(1):e84336.
31. Janowitz T. Biopharmaceuticals and monoclonal antibodies in oncology trials - a cross-sectional analysis. Protein Eng Des Sel. 2011;24(1-2):105-111.
32. Zarin D. Newsmaker interview: Debora Zarin. Unseen world of clinical trials emerges from US database. Interview by Eliot Marshall. Science. 2011;333(6039):145.
33. Inrig JK, Califf RM, Tasneem A, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis. 2014;63(5):771-780.
34. Hirsch BR, Califf RM, Cheng SK, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med. 2013;173(11):972-979.
35. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012;307(17):1838-1847.
36. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009;15(22):7029-7035.
37. Dayoub EJ, Davis MM. Relationship of therapeutic cancer vaccine development to population disease burden and five-year survival. Hum Vaccin. 2011;7(11):1124-1129.
38. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013;59(4):897-903.
39. Russ AJ, Wentworth L, Xu K, et al. Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011;18(13): 3848-3857.
40. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001;7(5):1181-1191.
41. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.